Literature DB >> 23027595

Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy?

Gennady Knyshov1, Vasyl Lazoryshynets, Kostyantyn Rudenko, Borys Kravchuk, Vyacheslav Beshlyaga, Valery Zalevsky, Olga Rasputnyak, Bogdan Batsak.   

Abstract

OBJECTIVES: Hypertrophic cardiomyopathy is a complex and relatively common genetic cardiac disease and has been the subject of intensive scrutiny and investigation for over 40 years. The aim of this non-randomized cohort study was to compare subjective and objective outcomes in hypertrophic cardiomyopathy patients undergoing drug therapy, surgical myotomy-myectomy, dual-chamber pacing and alcohol septal ablation.
METHODS: We examined 194 patients: 103 with non-obstructive hypertrophic cardiomyopathy and 91 with obstructive hypertrophic cardiomyopathy. All the patients with a non-obstructive form were on drug therapy. Ninety-one consecutive patients with drug-refractory obstructive hypertrophic cardiomyopathy were treated invasively. Dual-chamber pacemaker implantation was performed for 49 patients with previous positive temporary pacing test (Group 1). In 28 patients with massive left ventricle hypertrophy and obliteration of its cavities, extensive myotomy-myectomy was performed (Group 2). In 14 patients with midventricular obstruction and appropriate coronary anatomy, alcohol septal ablation was performed (Group 3).
RESULTS: The peak left ventricle outflow tract gradient was 84.1 ± 15.2 mmHg in Group 1, 113.3 ± 14.9 mmHg in Group 2 and 97.5 ± 8.9 mmHg in Group 3. Dual-chamber pacing in Group 1 with optimal atrio-ventricular delay (85-180 ms for atrium pacing and 45-120 ms for atrial sensing) leads to dramatic decreases in left ventricle outflow tract gradient to 17.6 ± 11.8 mmHg and degree of mitral regurgitation. After extensive myectomy in Group 2, we observed a reduction of left ventricle outflow tract gradient to 17.3 ± 10.2 mmHg. Septal alcohol ablation in Group 3 leads to a left ventricle outflow tract gradient decrease from 97.5 ± 8.9 to 25.3 ± 5.8 mmHg.
CONCLUSIONS: Surgical myectomy, dual-chamber pacing and alcohol septal ablation are equally effective in reducing obstruction in case of correct indications. Dual-chamber pacing is indicated in functional reversible states characterized by excitation delay. Alcohol septal ablation is preferable in cases with midventricular obstruction and appropriate coronary anatomy. Surgical methods are indicated in anatomical irreversible changes and remain the gold standard for obstructive hypertrophic cardiomyopathy treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23027595      PMCID: PMC3523618          DOI: 10.1093/icvts/ivs352

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  10 in total

Review 1.  Pacing in hypertrophic cardiomyopathy.

Authors:  L Kappenberger
Journal:  Eur Heart J       Date:  1999-02       Impact factor: 29.983

Review 2.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies.

Authors:  Mahboob Alam; Hisham Dokainish; Nasser Lakkis
Journal:  J Interv Cardiol       Date:  2006-08       Impact factor: 2.279

3.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients.

Authors:  H Seggewiss; U Gleichmann; L Faber; D Fassbender; H K Schmidt; S Strick
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

4.  Prognosis of patients with hypertrophic obstructive cardiomyopathy after transaortic myectomy. Late results up to twenty-five years.

Authors:  H D Schulte; W H Bircks; B Loesse; E A Godehardt; B Schwartzkopff
Journal:  J Thorac Cardiovasc Surg       Date:  1993-10       Impact factor: 5.209

5.  Effects of permanent dual-chamber pacing on mitral regurgitation in hypertrophic obstructive cardiomyopathy.

Authors:  D Pavin; C de Place; H Le Breton; C Leclercq; D Gras; F Victor; P Mabo; J C Daubert
Journal:  Eur Heart J       Date:  1999-02       Impact factor: 29.983

6.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy.

Authors:  Steve R Ommen; Barry J Maron; Iacopo Olivotto; Martin S Maron; Franco Cecchi; Sandro Betocchi; Bernard J Gersh; Michael J Ackerman; Robert B McCully; Joseph A Dearani; Hartzell V Schaff; Gordon K Danielson; A Jamil Tajik; Rick A Nishimura
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

7.  Management of symptomatic hypertrophic obstructive cardiomyopathy--long-term results after surgical therapy.

Authors:  H D Schulte; K Borisov; E Gams; H Gramsch-Zabel; B Lösse; B Schwartzkopff
Journal:  Thorac Cardiovasc Surg       Date:  1999-08       Impact factor: 1.827

8.  Percutaneous versus surgical treatment for patients with hypertrophic obstructive cardiomyopathy and enlarged anterior mitral valve leaflets.

Authors:  Chris van der Lee; Folkert J ten Cate; Marcel L Geleijnse; Marcel J Kofflard; Chiara Pedone; Lex A van Herwerden; Elena Biagini; Wim B Vletter; Patrick W Serruys
Journal:  Circulation       Date:  2005-07-18       Impact factor: 29.690

Review 9.  Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a review of the literature.

Authors:  Josef Veselka
Journal:  Med Sci Monit       Date:  2007-04

Review 10.  Inclusion of electric disturbance type cardiomyopathy in the classification of cardiomyopathy: a current review.

Authors:  Morie Sekiguchi; Atsuyo Hasegawa; Michiaki Hiroe; Shinichiro Morimoto; Toshio Nishikawa
Journal:  J Cardiol       Date:  2008-04       Impact factor: 3.159

  10 in total
  4 in total

1.  eComment. Septal reduction therapy for hypertrophic cardiomyopathy: the need of experienced centres.

Authors:  Ovidio A Garcia-Villarreal
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-01

2.  Alcohol Septal Ablation or Septal Myectomy? An Updated Systematic Review and Meta-Analysis of Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy.

Authors:  Xifeng Zheng; Bin Yang; Haosheng Hui; Bing Lu; Yinhui Feng
Journal:  Front Cardiovasc Med       Date:  2022-05-25

3.  Right ventricular pacing for hypertrophic obstructive cardiomyopathy: meta-analysis and meta-regression of clinical trials.

Authors:  Ahran D Arnold; James P Howard; Kayla Chiew; William J Kerrigan; Felicity de Vere; Hannah T Johns; Leonid Churlilov; Yousif Ahmad; Daniel Keene; Matthew J Shun-Shin; Graham D Cole; Prapa Kanagaratnam; S M Afzal Sohaib; Amanda Varnava; Darrel P Francis; Zachary I Whinnett
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-10-01

4.  Long-term clinical and echocardiographic outcomes of extensive septal myectomy for hypertrophic obstructive cardiomyopathy in Chinese patients.

Authors:  Lei Yao; Li Li; Xiong-Jun Lu; Yan-Ling Miao; Xiao-Ning Kang; Fu-Jian Duan
Journal:  Cardiovasc Ultrasound       Date:  2016-05-17       Impact factor: 2.062

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.